Opinion

Published within

« | ... | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

A&L/Abbey National: further consolidation may be on the cards

Alliance & Leicester is considered to be a prime target for a takeover bid. Recent reports suggest that Abbey National is one interested predator. This may be the start of a new round of domestic consolidation in the UK retail banking sector. However, the major players are likely to miss out for regulatory reasons.

Published By Datamonitor
08 Jan 2002
CommentWire
CommentWire

A&P: vintage grocer loses its frills

Following A&P's Q2 loss of $144.7 million, the company is turning to budget-conscious shoppers to boost flagging sales. Its new Food Basics 'mini-supermarkets' take their concept from the increasingly popular dollar stores. However, Food Basics will only pose competition for the likes of Wal-Mart if A&P can maintain low prices and consistent product availability.

Published By Datamonitor
25 Oct 2002
Expert View
Expert View

A-list celebrity endorsements are failing to dazzle consumers

A recent consumer survey has shown that celebrity endorsements are one of the least trusted means of conveying product information, only just faring better than door-dropped leaflets. This is bad news for advertising agencies, which have been devoting increased energy to signing up everyone from bona fide A-list stars to Z-list reality show contestants to help sell products and services.

Published By Datamonitor
21 Jul 2006
CommentWire
CommentWire

AA / Shoosmiths: a personal injury push

The AA's partnership with Shoosmiths will allow it to compete with RAC's blossoming legal services division and capitalize on new opportunities in the sector. The services group's timing is appropriate, as regulatory changes in the law profession are likely to see a raft of familiar retail brands offering legal services. Like RAC, the AA is well placed at the vanguard of this shift.

Published By Datamonitor
21 Apr 2005
CommentWire
CommentWire

AA/Saga: insurer looks set to benefit from proposed in-house credit hire operations

In a move to tackle the costs associated with credit hire, AA/Saga plans to bring its arrangements in-house. Credit hire costs are a major source of claims inflation for motor insurers, and bringing credit hire in-house could generate a lucrative side line, while also giving it greater control over a key driver in claims costs.

Published By Datamonitor
16 Jul 2009
CommentWire
CommentWire

AA: the road to success

After its recent acquisition by private equity houses CVC and Permira, the AA has announced a major restructuring including an exit from the car servicing business and cutbacks of up to 1,300 jobs. The moves will create a more efficient, streamlined and profitable company.

Published By Datamonitor
11 Oct 2004
Expert View
Expert View

AAN 2010: late-stage pipeline candidates take center stage in migraine

In the wake of Imitrex's and Topamax's patent expiries, announcements at this year's American Academy of Neurology meeting focused firmly on the next major breakthroughs for the acute and prophylactic migraine markets. Pooled data for candidates from Allergan and Merck & Co demonstrated impressive potential, suggesting renewed hope for sufferers.

Published By Datamonitor
20 Apr 2010
Expert View
Expert View

AAN 2010: new treatments address unmet needs in Alzheimer's and epilepsy

A number of leading drug makers used this year's meeting of the American Academy of Neurology to present new data for promising pipeline candidates. Despite promising results, however, Datamonitor believes that the epilepsy drugs will struggle to find their place in the market. Moreover, the positive Phase II data for Baxter's potential Alzheimer's therapy Gammagard do not guarantee later success.

Published By Datamonitor
20 Apr 2010
Expert View
Expert View

AAN 2010: spotlight shines on Novartis' and Merck KGaA's oral MS candidates

Datamonitor attended this year's American Academy of Neurology conference, where developments in multiple sclerosis took precedence for the third consecutive year. Both Novartis and Merck KGaA presented new data for their pipeline candidates, while Acorda used the meeting as a platform to share data for its symptomatic treatment Ampyra, which was recently approved by the FDA.

Published By Datamonitor
20 Apr 2010
Expert View
Expert View

AAN 2011: Gilenya raises the bar for prospective MS market entrants

Datamonitor recently attended the 63rd American Academy of Neurology Annual Meeting in Honolulu, Hawaii, held over April 9-16, 2011. For another year running, developments in multiple sclerosis (MS) treatment research dominated proceedings. Below are the highlights of the conference's coverage of new multiple sclerosis drugs.

Published By Datamonitor
03 May 2011

« | ... | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | ... | » »|

No help is available.